Back to Journals » Clinical Ophthalmology » Volume 6

Hemianopia and visual loss due to progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis

Authors Herold, Jakl, Graser, Eibl K

Received 7 February 2012

Accepted for publication 6 March 2012

Published 18 July 2012 Volume 2012:6 Pages 1131—1133

DOI https://doi.org/10.2147/OPTH.S30636

Review by Single-blind

Peer reviewer comments 4


Tina Rike Herold,1 Veronika Jakl,3 Anno Graser,4 Kirsten Eibl-Lindner1,2

1
Department of Ophthalmology, 2Department of Ophthalmology, Campus Innenstadt, 3Department of Neurology, 4Department of Clinical Radiology, Campus Grosshadern, University of Munich, Ludwig-Maximilians University, Munich, Germany

Abstract: This case describes typical ophthalmic findings as a key feature for diagnosis of progressive multifocal leukoencephalopathy (PML) and its possible differential diagnosis. A 58-year-old female patient with relapsing-remitting multiple sclerosis on immunotherapy with natalizumab developed visual disturbance, reading problems, and visual field defects due to PML. PML is a reactivation of latent infection with the John Cunningham virus, which is a type of polyomavirus acquired in childhood or adolescence and is quite common in the general population. PML so far has been mostly associated with other immunodeficiency disorders, such as acquired immunodeficiency syndrome, but is also gaining importance in association with the increasing use and duration of treatment with natalizumab in patients suffering from multiple sclerosis. Natalizumab is a highly specific α4-integrin antagonist approved for treatment of patients with active relapsing-remitting multiple sclerosis.

Keywords: progressive multifocal leukoencephalopathy, natalizumab, multiple sclerosis, hemianopia

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]